The New Design Standard for Clinical Trials
Based on a 2013 study with Novartis for BioMedical Research, TKL Research developed a study that was approved and accepted by the FDA as a comprehensive design to test the photosensitization potential of the investigational product. We propose this methodology to be used as the new standard for photosensitivity clinical trials as this approach includes a positive control, confirming that it allows for the detection of photosensitization.
For inquiries please contact:
Gregory R. Anderson
Vice President, Business Development